This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| PRS | |
|---|---|
| Name | PRS |
| Type | Quantitative index |
| Field | Genetics; Medicine; Epidemiology |
| Introduced | 2000s |
| Components | Polygenic scores; Risk alleles; Genome-wide association studies |
PRS
Polygenic risk scoring systems aggregate genetic information to estimate predisposition to complex traits and diseases. Developed from large-scale Genome-wide association studys and population cohorts such as UK Biobank and Framingham Heart Study, these scores inform research in Cardiovascular disease, Type 2 diabetes, and psychiatric conditions like Schizophrenia and Major depressive disorder. Contemporary work connects scores to translational efforts in institutions including Harvard University, Broad Institute, Wellcome Trust, and National Institutes of Health.
Polygenic risk indices quantify inherited susceptibility by summing allelic effects estimated from Genome-wide association studys performed by consortia such as the International HapMap Project, Psychiatric Genomics Consortium, and GIANT Consortium. Use spans clinical cohorts like All of Us Research Program and biobanks such as BioBank Japan and deCODE genetics, and informs research on outcomes catalogued in resources like ClinVar and dbSNP. Implementation involves tools developed at centers including Stanford University, University of Cambridge, Max Planck Institute for Psycholinguistics, and companies such as 23andMe and Illumina.
Early conceptual roots trace to quantitative genetics work by Ronald Fisher and J.B.S. Haldane, with methodological advances driven by genotyping platforms from Affymetrix and Illumina and landmark studies like the Wellcome Trust Case Control Consortium. The rise of large-scale consortiums—ENIGMA Consortium, CARDIoGRAMplusC4D, and GIANT Consortium—plus computational frameworks from Broad Institute and Sanger Institute enabled genome-wide effect estimation. Population resources including UK Biobank and Framingham Heart Study provided phenotype linkage, while statistical innovations by researchers at Princeton University, University of Michigan, and Columbia University improved portability and accuracy.
Calculation typically uses summary statistics from Genome-wide association studys produced by groups such as Psychiatric Genomics Consortium or GIANT Consortium, combined with linkage disequilibrium reference panels like 1000 Genomes Project and HapMap. Methods include pruning-and-threshold, Bayesian approaches exemplified by software from labs at Massachusetts Institute of Technology and University of Oxford, and penalized regression developed in centers like University of California, Berkeley. Quality control pipelines reference variant annotation resources such as dbSNP and effect catalogs like ClinVar, often leveraging computing infrastructure at National Center for Biotechnology Information and cloud providers used by European Bioinformatics Institute.
Research applications encompass risk stratification in Coronary artery disease studies by CARDIoGRAMplusC4D and prediction of Alzheimer's disease in cohorts affiliated with Alzheimer's Association research. Clinical translational pilots occur in settings linked to Mayo Clinic, Cleveland Clinic, and academic hospitals like Johns Hopkins Hospital. Public-health modeling collaborations with agencies such as Centers for Disease Control and Prevention explore screening strategies. In pharma, groups at Pfizer, Novartis, and GlaxoSmithKline use scores for cohort selection and pharmacogenomic studies tied to programs at European Medicines Agency and Food and Drug Administration.
Performance varies across ancestries represented in reference datasets, as documented in comparisons involving UK Biobank, BioBank Japan, and H3Africa cohorts. Transferability issues highlighted by teams at Stanford University and University of California, San Francisco reflect allele frequency and linkage disequilibrium differences measured in 1000 Genomes Project populations. Validation strategies employ independent cohorts such as Framingham Heart Study and prospective trials coordinated by institutions like NCI and NIH Clinical Center. Limitations include modest absolute risk prediction for many outcomes, uncertainty in rare variant contributions cataloged in gnomAD, and potential confounding from population structure noted in studies by Princeton University and Harvard Medical School.
Equity concerns arise when scores developed in European-ancestry datasets like UK Biobank are applied to underrepresented groups studied in H3Africa or All of Us Research Program, prompting responses from organizations such as WHO and NHGRI. Issues of informed consent and data sharing engage stakeholders including Council for International Organizations of Medical Sciences and Global Alliance for Genomics and Health. Legal considerations involve discrimination protections under frameworks like Genetic Information Nondiscrimination Act and policy discussions by bodies such as European Commission and national ethics councils. Community engagement examples include partnerships with Indigenous Peoples Council on Biocolonialism and patient-advocacy groups like Alzheimer's Association and American Heart Association.
Clinical deployment intersects regulatory review by the Food and Drug Administration and reimbursement deliberations influenced by agencies such as Centers for Medicare & Medicaid Services and National Institute for Health and Care Excellence. Guidelines from professional societies—American College of Cardiology, American Heart Association, American Psychiatric Association—shape adoption pathways, while pilot implementation studies in systems like NHS England and Veterans Health Administration test utility. Laboratory standards reference accreditation bodies such as College of American Pathologists and frameworks from Clinical Laboratory Improvement Amendments-related authorities.